PT - JOURNAL ARTICLE AU - Rane, Madhura S. AU - Kochhar, Shivani AU - Poehlin, Emily AU - You, William AU - Robertson, McKaylee AU - Zimba, Rebecca AU - Westmoreland, Drew AU - Romo, Matthew AU - Kulkarni, Sarah AU - Chang, Mindy AU - Berry, Amanda AU - Grov, Christian AU - Nash, Denis AU - , TI - Determinants of COVID-19 vaccine hesitancy and vaccine uptake in a national cohort of U.S. adults AID - 10.1101/2021.05.12.21257116 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.12.21257116 4099 - http://medrxiv.org/content/early/2021/05/15/2021.05.12.21257116.short 4100 - http://medrxiv.org/content/early/2021/05/15/2021.05.12.21257116.full AB - Background Vaccine hesitancy in the U.S. may limit the potential to alleviate the public health threat caused by the COVID-19 pandemic.Methods We estimated trends in and correlates of vaccine hesitancy, and its association with subsequent vaccine uptake among 5,085 United States adults from the CHASING COVID Cohort study, a national longitudinal study. Trends in willingness to vaccinate were examined longitudinally in three rounds of interviews from September to December 2020. We assessed correlates of willingness to vaccinate in December 2020. We also estimated the association between willingness to vaccinate in December 2020 and subsequent vaccine uptake in February 2021.Results Vaccine hesitancy and resistance decreased from 51% and 8% in September 2020 to 35% and 5% in December 2020, respectively. Compared to Non-Hispanic (NH) White participants, NH Black and Hispanic participants had higher adjusted odds ratios (aOR) for both vaccine hesitancy (aOR: 3.3 [95% CI: 2.6, 4.2] for NH Black and 1.8 [95% CI: 1.5, 2.2] for Hispanic) and vaccine resistance (aOR: 6.4 [95% CI: 4.3, 9.4] for NH Black and 1.9 [95% CI: 1.3, 2.7] for Hispanic). Willingness to vaccinate was associated with lower odds of vaccine uptake among 65+ year olds (aOR: 0.4, 95% CI: 0.3, 0.6 for hesitancy; aOR: 0.1, 95% CI: 0.01, 0.6 for resistance) and healthcare workers (aOR: 0.2, 95% CI: 0.1, 0.3 for hesitancy; aOR: 0.04, 95% CI: 0.006, 0.2 for resistance).Conclusions Awareness and distribution efforts should focus on vaccine hesitant vulnerable populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this project is provided by The National Institute of Allergy and Infectious Diseases (NIAID), award number 3UH3AI133675-04S1 (MPIs: D Nash and C Grov), the CUNY Institute for Implementation Science in Population Health (cunyisph.org) and the COVID-19 Grant Program of the CUNY Graduate School of Public Health and Health Policy, and National Institute of Child Health and Human Development grant P2C HD050924 (Carolina Population Center). The NIH played no role in the production of this manuscript nor necessarily endorses the findings.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Institutional Review Board at the City University of New York (CUNY).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referenced in the manuscript are available upon request.